Formula Growth’s Albemarle ALB Stock Holding History

Formula Growth’s Portfolio ALB Stock Details ALB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-12,000	Closed	-$1.73M	–	113
2023 Q4	$1.73M	Buy	+12,000	New	+$1.65M	0.56%	77
2022 Q2	–	Sell	-21,000	Closed	-$4.64M	–	131
2022 Q1	$4.64M	Buy	+21,000	New	+$4.44M	0.88%	43
2020 Q1	–	Sell	-96,785	Closed	-$7.07M	–	154
2019 Q4	$7.07M	Buy	+96,785	New	+$6.46M	0.89%	35

Other funds holding ALB

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $299B AUM 28.69% 1-Year Est. Return

Formula Growth's ALB Position: Q1 2024 in Review

Formula Growth sold out of Albemarle (ALB) in Q1 2024, closing a stake of 12,000 shares — an estimated $1.73M sold.

Formula Growth first reported a position in ALB in Q4 2019 and held it in 3 quarters. The position peaked at $7.07M in Q4 2019. 916 funds tracked by Wall St. Rank hold ALB as of Q1 2024.

Formula Growth reported no remaining Albemarle position as of Q1 2024 after selling out during the quarter.
Formula Growth sold 12,000 Albemarle shares in Q1 2024, an estimated $1.73M.
Formula Growth first reported a position in Albemarle in Q4 2019 and held it in 3 quarters.
Formula Growth's Albemarle position peaked at $7.07M in Q4 2019.
916 funds tracked by Wall St. Rank held Albemarle as of Q1 2024.

Based on Formula Growth's 13F filing for Q1 2024, filed 14 May 2024.